natgillin/translations-raw huggingface dataset:
The active substances in Epclusa, sofosbuvir and velpatasvir, block two proteins essential for the hepatitis C virus to multiply.
Zdravilni učinkovini zdravila Epclusa, sofosbuvir in velpatasvir, zavirata dve beljakovini, ki ju virus hepatitisa C potrebuje za razmnoževanje.
Epclusa on its own has been shown to be highly effective in clearing the hepatitis C virus from the blood of patients whose liver is able to work adequately.
Samostojno uporabljeno zdravilo Epclusa se je izkazalo za visoko učinkovito pri odstranjevanju virusa hepatitisa C iz krvi bolnikov, ki imajo delujoča jetra.
Epclusa is an antiviral medicine used to treat adults with chronic (long-term) hepatitis C, an infectious disease that affects the liver, caused by the hepatitis C virus.
Zdravilo Epclusa je protivirusno zdravilo, namenjeno zdravljenju odraslih s kroničnim (dolgotrajnim) hepatitisom C (nalezljivo boleznijo, ki prizadene jetra in jo povzroča virus hepatitisa C).
For the full list of side effects or restrictions with Epclusa, see the package leaflet.
Za celoten seznam neželenih učinkov ali omejitev pri uporabi zdravila Epclusa glejte navodilo za uporabo.
The addition of ribavirin to Epclusa may also be considered for patients who have compensated liver cirrhosis (scarring of the liver but the liver is still able to work adequately) and are infected with genotype 3 hepatitis C virus, a variety which is more difficult to treat.
O dodatku ribavirina zdravilu Epclusa se lahko razmisli tudi pri bolnikih s kompenzirano cirozo jeter (brazgotinjenjem jeter, pri čemer jetra še vedno delujejo), okuženih z virusom hepatitisa C z genotipom 3, različico, ki se težje zdravi.
An additional study was carried out in 267 hepatitis C patients whose liver was not working properly (Child-Pugh class B cirrhosis).
Pri 267 bolnikih s hepatitisom C, pri katerih jetra niso delovala pravilno (ciroza stopnje B po ChildPughu), so opravili dodatno študijo.
Epclusa contains the active substances sofosbuvir and velpatasvir.
Zdravilo Epclusa vsebuje zdravilni učinkovini sofosbuvir in velpatasvir.
Looking at the results of the studies together, 98% of patients (1,015 out of 1,035) taking Epclusa for 12 weeks tested negative for the virus 12 weeks after the end of treatment.
Glavno merilo učinkovitosti v vseh treh študijah je bilo število bolnikov, pri katerih krvne preiskave 12 tednov po koncu zdravljenja niso pokazale prisotnosti virusa hepatitisa C. Skupna analiza rezultatov študij je pokazala, da so bili pri 98 % bolnikov (1 015 od 1 035), ki so 12 tednov jemali zdravilo Epclusa, testi za virus 12 tednov po koncu zdravljenja negativni.
How is Epclusa used?
Kako se zdravilo Epclusa uporablja?
How does Epclusa work?
Kako zdravilo Epclusa deluje?
Epclusa is taken with another medicine called ribavirin in patients with decompensated liver disease (when the liver is not working properly).
Bolniki z dekompenzirano boleznijo jeter (nepravilnim delovanjem jeter) zdravilo Epclusa jemljejo skupaj z drugim zdravilom, imenovanim ribavirin.
112 capsules
112 kapsul
Capsule, soft
40 mg kapsule, mehke peroralna uporaba
Estimated difference
Ocenjena razlika
There are no adequate and well controlled studies in lactating women.
Ni zadostnih in dobro kontroliranih študij pri doječih ženskah.
• if you are taking riociguat.
- če jemljete riociguat.
The causes of deaths were related to
Vzroki smrti so bili povezani s PAH.
• lose a large amount of body fluids (dehydration) which can occur when you sweat a lot or do not drink enough liquids.
- izgubite veliko količino telesnih tekočin (dehidracija), kar se lahko pojavi, ko se čezmerno potite ali ne pijete dovolj tekočin.
This medicinal product does not require any special storage condition.
To zdravilo ne potrebuje posebnih pogojev za shranjevanje.
• if you have recently had a stroke, a heart attack or if you have severe liver disease or very low blood pressure (<90/50 mmHg).
- če ste nedavno doživeli možgansko kap ali srčni infarkt ali če imate hudo bolezen jeter ali zelo nizek krvni tlak (< 90/50 mm Hg).
The safety and efficacy of sildenafil in children below 1 year of age has not been established.
Varnost in učinkovitost sildenafila pri otrocih, mlajših od 1 leta, nista bili dokazani.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo:
In-vitro studies
Študije in vitro
• take medicines for erectile dysfunction.
- jemljete zdravila za zdravljenje erektilne disfunkcije.
Mysildecard passes into your breast milk at very low levels and would not be expected to harm your baby.
Zdravilo Mysildecard prehaja v vaše mleko v zelo majhni količini in ni pričakovati, da bi to škodovalo vašemu otroku.
• Blood thinning medicines (for example warfarin) although these did not result in any side effect.
• zdravila proti strjevanju krvi (npr. varfarin), čeprav ta niso povzročila nobenih neželenih učinkov.
Tablets should be taken approximately 6 to 8 hours apart with or without food.
Tablete naj se vzame približno 6 do 8 urim razmakom, s hrano ali brez nje.
Prescribers should carefully assess the mother's clinical need for sildenafil and any potential adverse effects on the breast-fed child.
Predpisovalci morajo skrbno oceniti klinično potrebo matere po sildenafilu in kakršne koli neželene učinke na dojenega otroka.
Serious adverse events were reported in 94 (41%) of the 229 subjects receiving sildenafil.
O resnih neželenih učinkih so poročali pri 94 (41%) od 229 preiskovancev, ki so prejemali sildenafil.
Similarly 191 of 229 subjects (83%) who had received sildenafil had either maintained or improved their WHO Functional Class at 1 year assessment.
Podobno se je pri 191 od 229 preiskovancev (83%), ki so prejemali sildenafil, po enem letu ocenjevanja funkcijski razred po SZO ohranil ali izboljšal.
• have a severe heart problem.
- imate kakšno hudo težavo s srcem.
• Severe hypotension (blood pressure < 90/50 mmHg) at initiation.
• s hudo hipotenzijo (krvni tlak < 90/50 mm Hg) ob uvedbi.
Do not take Mysildecard: • if you are allergic to sildenafil or any of the other ingredients of this medicine (listed in section
Ne uporabljajte zdravila Mysildecard: - če ste alergični na sildenafil ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Mean pulmonary systolic blood pressure decreased by 9%.
Povprečni pljučni sistolični krvni tlak se je znižal za 9%.
The tablets are marked with M on one side and SL over 20 on the other.
Na eni strani imajo oznako M in na drugi SL preko 20.
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer(s) responsible for batch release Mylan Hungary Kft.
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov izdelovalca, odgovornega za sproščanje serij Mylan Hungary Kft.
If you forget to take Mysildecard, take a dose as soon as you remember, then continue to take your medicine at the usual times.
Če pozabite vzeti zdravilo Mysildecard, vzemite odmerek, čim se spomnite, potem pa nadaljujte z jemanjem zdravila ob običajnem času.
Mysildecard has moderate influence on the ability to drive and use machines.
Zdravilo Mysildecard ima zmeren vpliv na sposobnost vožnje in upravljanja strojev.
• have an abnormality of red blood cells (sickle cell anaemia), cancer of blood cells (leukaemia),
- imate nepravilnost rdečih krvnih celic (srpastocelično anemijo), raka krvnih celic (levkemijo),
No clinical data are available regarding adverse events in breast-fed infants, but amounts ingested would not be expected to cause any adverse effects.
Na voljo ni kliničnih podatkov glede neželenih učinkov pri dojenih otrocih, toda ni pričakovati, da bi zaužita količina povzročila kakršne koli neželene učinke.
Sildenafil and its major circulating N-desmethyl metabolite are approximately 96% bound to plasma proteins.
Sildenafil in njegov glavni krožeči N-dezmetilni presnovek sta približno 96% vezana na beljakovine v plazmi.
Sildenafil had no significant effect on atorvastatin exposure (AUC increased 11%), suggesting that sildenafil does not have a clinically relevant effect on CYP3A4.
Sildenafil ni pomembno vplival na izpostavljenost atorvastatinu (AUC se je povečala za 11%), kar kaže, da nima klinično pomembnega vpliva na CYP3A4.
Due to age-differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately
Zaradi starostnih razlik v vezavi na beljakovine v plazmi so se ustrezne plazemske koncentracije prostega sildenafila povečale za približno
Mysildecard film-coated tablets are white and round in shape.
Filmsko obložene tablete Mysildecard so bele in okrogle oblike.
Physicians should advise patients who forget to take Mysildecard to take a dose as soon as possible and then continue with the normal dose.
Zdravniki naj bolnikom svetujejo, da v primeru, da pozabijo vzeti zdravilo Mysildecard, vzamejo odmerek takoj, ko je možno in nato nadaljujejo z normalnim odmerkom.
• Therapies for pulmonary hypertension (e.g. bosentan, iloprost)
• zdravila za zdravljenje pljučne hipertenzije (npr. bosentan, iloprost).
Limited data suggests that the abrupt discontinuation of sildenafil is not associated with rebound worsening of pulmonary arterial hypertension.
Omejeni podatki kažejo, da nenadne prekinitve uporabe sildenafila ne spremlja povratno poslabšanje pljučne arterijske hipertenzije.
• if you are taking a medicine to treat fungal infections such as ketoconazole or itraconazole or medicines containing ritonavir (for HIV).
- če jemljete zdravila za zdravljenje glivičnih okužb, kot sta ketokonazol ali itrakonazol ali zdravila, ki vsebujejo ritonavir (za HIV).
Mylan S.A.S 117 Allee des parcs 69800 Saint Priest France
Mylan S.A.S 117 Allee des parcs 69800 Saint Priest Francija
Data from one lactating woman indicate that sildenafil and its active metabolite N-desmethylsildenafil are excreted into breast milk at very low levels.
Podatek od ene doječe ženske kaže, da se sildenafil in njegov aktivni presnovek N-desmetilsildenafil izločata v materino mleko v zelo majhni količini.
90 film-coated tablets 300 film-coated tablets 90 x 1 film-coated tablets
90 filmsko obloženih tablet 300 filmsko obloženih tablet 90 x 1 filmsko obložena tableta
What Mysildecard is and what it is used for
Kaj je zdravilo Mysildecard in za kaj ga uporabljamo
When sildenafil is taken with food, the rate of absorption is reduced with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29% however, the extent of absorption was not significantly affected (AUC decreased by 11%).
Če sildenafil zaužijemo s hrano, se hitrost absorpcije zmanjša s povprečno zakasnitvijo tmax 60 minut in povprečnim zmanjšanjem Cmax za 29%, delež absorpcije pa se pomembneje ne zmanjša (zmanjšanje AUC za 11%).
The proportion of subjects receiving supportive medicinal products at baseline (anticoagulants, digoxin, calcium channel blockers, diuretics and/or oxygen) was similar in the combined sildenafil treatment group (47.7%) and the placebo treatment group (41.7%).
Delež preiskovancev, ki so na začetku prejemali podporno zdravljenje (antikoagulante, digoksin, zaviralce kalcijevih kanalčkov, diuretike in/ali kisik), je bil podoben v združeni skupini, ki je prejemala sildenafil (47,7%) in v skupini, ki je prejemala placebo (41,7%).
When sildenafil and doxazosin were administered simultaneously to patients stabilised on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension.
Ko so sildenafil in doksazosin sočasno uporabili pri bolnikih, stabiliziranih na zdravljenju z doksazosinom, so poročali o redkih primerih simptomatske posturalne hipotenzije.
Women of childbearing potential and contraception in males and females Due to lack of data on effects of sildenafil in pregnant women, Mysildecard is not recommended for women of childbearing potential unless also using appropriate contraceptive measures.
Ženske v rodni dobi in kontracepcija pri moških in ženskah Zaradi nezadostnih podatkov o učinkih sildenafila pri nosečnicah, uporaba zdravila Mysildecard ni priporočljiva pri ženskah v rodni dobi, razen v primeru, da uporabljajo tudi ustrezne ukrepe za preprečevanje nosečnosti.
In case of clinical deterioration in spite of Mysildecard treatment, alternative therapies should be considered.
Če se klinično stanje kljub zdravljenju z zdravilom Mysildecard poslabša, je treba pretehtati druge možnosti zdravljenja.
• have high blood pressure in the blood vessels in the lungs.
- imate zvišan krvni tlak v krvnih žilah v pljučih.
A white, round, biconvex film-coated tablet (approximately 6.5 mm diameter), debossed with M on one side of the tablet and SL over 20 on the other side.
Bela, okrogla, na obeh straneh izbočena filmsko obložena tableta (premera približno 6,5 mm) z vtisnjenim M na eni strani tablete in SL preko 20 na drugi strani.
The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated:
Ker varnost sildenafila ni raziskana v naslednjih podskupinah bolnikov, je uporaba sildenafila pri leteh kontraindicirana:
Patients were randomised to placebo or sildenafil (20 mg three times a day) in combination with bosentan (62.5-125 mg twice a day).
Bolnike so randomizirali na placebo ali sildenafil (20 mg trikrat na dan) v kombinaciji z bosentanom (62,5 - 125 mg dvakrat na dan).
• Recent history of stroke or myocardial infarction,
• z anamnezo o nedavni možganski kapi ali miokardnem infarktu,
• have a rare inherited eye disease (retinitis pigmentosa).
- imate redko dedno očesno bolezen (pigmentozni retinitis).
The PAH patients included those with Primary Pulmonary Arterial Hypertension (212/267, 79%) and PAH associated with connective tissue disease (55/267, 21%).
Med bolniki s PAH so bili takšni s primarno pljučno arterijsko hipertenzijo (212/267, 79%) in takšni s PAH, povezano z boleznimi vezivnega tkiva (55/267, 21%).
Film coat: hypromellose (6mPas), titanium dioxide (E171) and triacetin.
Filmska obloga: hipromeloza (6mPas), titanov dioksid (E171) in triacetin.
Mysildecard is for oral use only.
Zdravilo Mysildecard je le za peroralno uporabo.
117 Allee des parcs 69800 Saint Priest France
117 Allee des parcs 69800 Saint Priest Francija
23 subjects experienced clinical worsening events in the placebo group (17.6%) compared with 8 subjects in the sildenafil group (6.0%).
V skupini s placebom je 23 preiskovancev (17,6%) doživelo klinično poslabšanje v primerjavi z 8 preiskovanci v skupini s sildenafilom (6,0%).
Mysildecard can cause a serious increase in the effects of these medicines.
Zdravilo Mysildecard lahko močno poveča njihov učinek.
A total of 234 subjects aged 1 to 17 years were treated in a randomised, double-blind, multi-centre, placebo controlled parallel group, dose ranging study.
Skupno 234 preiskovancev, starih od 1 leta do 17 let, je sodelovalo v randomizirani, dvojno slepi, multicentrični, s placebom nadzorovani študiji z vzporednima skupinama, v kateri je bil uporabljen niz odmerkov.
The corresponding additional reduction in supine diastolic blood pressure was 7 mmHg.
Ustrezno dodatno znižanje diastoličnega krvnega tlaka v ležečem položaju je bilo 7 mm Hg.
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 > 150 μM).
Sildenafil je šibek zaviralec izoencimov 1A2, 2C9, 2C19, 2D6, 2E1 in 3A4 citokroma P450 (IC50 > 150 M).
Mysildecard with food and drink You should not drink grapefruit juice while you are being treated with Mysildecard.
Zdravilo Mysildecard skupaj s hrano in pijačo Med zdravljenjem z zdravilom Mysildecard ne smete piti grenivkinega soka.
• Tell your doctor or pharmacist if you are already taking riociguat (see section 2).
• če že jemljete riociguat, to povejte zdravniku ali farmacevtu (glejte poglavje 2).
The efficacy of sildenafil has not been established in patients with severe pulmonary arterial hypertension (functional class IV).
Učinkovitost sildenafila ni ugotovljena pri bolnikih s hudo pljučno arterijsko hipertenzijo (funkcijski razred IV).
Suddenly stopping your treatment with Mysildecard may lead to your symptoms getting worse.
Če zdravilo Mysildecard nehate jemati nenadoma, se vam simptomi lahko poslabšajo.
Mysildecard contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Zdravilo Mysildecard vsebuje zdravilno učinkovino sildenafil, ki sodi med zdravila, ki jih imenujemo zaviralci fosfodiesteraze tipa 5 (PDE5).
Of those sildenafil treated subjects developmentally able to perform the CPET 59/114 subjects (52%) had not shown any deterioration in Peak VO2 from start of sildenafil.
Izmed tistih preiskovancev, zdravljenih s sildenafilom, ki so bili glede na razvoj sposobni opraviti CPET, pri 59 izmed 114 preiskovancev (52%) niso ugotovili nobenih odstopanj pri največji vrednosti VO2 od začetka uporabe sildenafila.
What you need to know before you take Mysildecard
Kaj morate vedeti, preden boste vzeli zdravilo Mysildecard
As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they might be affected by Mysildecard, before driving or using machines.
V kliničnih preskušanjih s sildenafilom so poročali o omotici in spremembah vida, zato morajo biti bolniki pred vožnjo ali upravljanjem s stroji seznanjeni, kako lahko zdravilo Mysildecard nanje vpliva.
What Mysildecard is and what it is used for What you need to know before you take Mysildecard How to take Mysildecard
Kaj je zdravilo Mysildecard in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Mysildecard Kako jemati zdravilo Mysildecard Možni neželeni učinki
Sildenafil is contraindicated in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.3).
Sildenafil je kontraindiciran pri bolnikih s hudo okvaro jeter (razred C po Child-Pughu) (glejte poglavje 4.3).
• Severe hepatic impairment,
• s hudo okvaro jeter,
• Medicines containing St. John's Wort (herbal medicinal product), rifampicin (used to treat bacterial infections), carbamazepine, phenytoin and phenobarbital (used, among others, to treat epilepsy)
• zdravila, ki vsebujejo šentjanževko (zeliščno zdravilo), rifampicin (uporablja se za zdravljenje bakterijskih okužb), karbamazepin, fenitoin ali fenobarbital (med drugim se uporabljata za zdravljenje epilepsije).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: DD month YYYY
Datum prve odobritve: DD mesec LLLL
175 patients (63%) included were diagnosed with primary pulmonary hypertension, 84 (30%) were diagnosed with PAH associated with connective tissue disease and 18 (7%) of the patients were diagnosed with PAH following surgical repair of congenital heart lesions.
175 vključenih bolnikov (63%) je imelo diagnosticirano primarno pljučno hipertenzijo, 84 (30%) PAH, povezano z boleznimi vezivnega tkiva, in 18 (7%) PAH po kirurški popravi prirojenih srčnih hib.
Taking more Mysildecard than you should may increase the risk of known side effects.
Večji odmerek zdravila Mysildecard, kot je dovoljen, lahko poveča tveganje znanih neželenih učinkov.
Subjects (38% male and 62% female) had a body weight ≥8 kg, and had primary pulmonary hypertension (PPH) [33%], or PAH secondary to congenital heart disease [systemic-to-pulmonary shunt 37%, surgical repair 30%].
Preiskovanci (38% moških in 62% žensk) so imeli telesno maso  8 kg, in so imeli primarno pljučno hipertenzijo (PPH) [33%] ali PAH kot posledico prirojenega srčnega obolenja [sistemsko-pljučni spoj 37%, odprava težave s kirurškim posegom 30%].
In this trial, 63 of 234 (27%) patients were < 7 years old (sildenafil low dose = 2; medium dose = 17; high dose = 28; placebo = 16) and 171 of 234 (73%) patients were 7 years or older (sildenafil low dose = 40; medium dose = 38; and high dose = 49; placebo = 44).
V tem preskušanju je bilo 63 od 234 (27%) bolnikov starih < 7 let (majhen odmerek sildenafila = 2; srednji odmerek = 17; velik odmerek = 28; placebo = 16), 171 od 234 (73%) bolnikov pa je bilo starih 7 let ali več (majhen odmerek sildenafila = 40; srednji odmerek = 38; in velik odmerek = 49; placebo = 44).
Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 90% higher plasma concentrations of sildenafil and the active N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 years).
Zdravi starejši prostovoljci (stari 65 let ali več) so imeli manjši očistek sildenafila, zato je bila koncentracija sildenafila in aktivnega N-dezmetilnega presnovka v plazmi pri njih približno 90% večja kot pri mlajših zdravih prostovoljcih (starih od 18 do 45 let).
Common pyrexia *These adverse events/reactions have been reported in patients taking sildenafil for the treatment of male erectile dysfunction (MED).
Splošne težave in spremembe na mestu aplikacije pogosti pireksija * O teh neželenih učinkih/reakcijah so poročali pri bolnikih, ki so sildenafil jemali za zdravljenje moške erektilne disfunkcije (MED).
In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively were observed.
V teh študijskih populacijah so opazili povprečno dodatno znižanje krvnega tlaka v ležečem položaju za 7/7 mm Hg, 9/5 mm Hg oz. 8/4 mm Hg ter dodatno znižanje krvnega tlaka v stoječem položaju za 6/6 mm Hg, 11/4 mm Hg in 4/5 mm Hg.
Patients with left ventricular ejection fraction < 45% or left ventricular shortening fraction < 0.2 were not studied.
Študija ni proučevala bolnikov z iztisnim deležem levega prekata < 45% ali skrčitvenim deležem levega prekata < 0,2.
Mysildecard should not be used during pregnancy unless strictly necessary.
Zdravila Mysildecard ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
If you have an erection, which lasts continuously for more than 4 hours, stop taking Mysildecard and contact your doctor immediately (see also section 4).
Če imate erekcijo, ki nepretrgano traja dlje kot 4 ure, prenehajte jemati zdravilo Mysildecard in nemudoma obvestite zdravnika (glejte tudi poglavje 4).
In a specific interaction study, where sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8 mmHg.
V specifični interakcijski študiji, v kateri so hipertenzivni bolniki dobivali sildenafil (100 mg) sočasno z amlodipinom, se je sistolični krvni tlak v ležečem položaju dodatno znižal za 8 mm Hg.
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline.
V študiji hemodinamskih učinkov posamičnega 100 mg peroralnega odmerka sildenafila pri 14 bolnikih s hudo boleznijo koronarnih arterij (> 70% stenoza vsaj ene koronarne arterije) se je povprečni sistolični tlak v mirovanju v primerjavi z izhodiščem znižal za 7%, povprečni diastolični v mirovanju pa za 6%.